Indian pharmaceutical companies exporting medicines worth $1 billion to at least a dozen countries like Brazil, Mexico, China and Germany are finding non-tariff barriers, in the form of discriminatory treatments, hampering their export prospect.
Besides Novartis, the other companies are Roche, J&J, Glaxo and Astrazeneca.
This has prompted public health groups to call the concerns of Swiss drug major Novartis that inadequacies in Indian patent law will have negative consequences for patients and public health in India as 'bogus'.
The central government is considering an expansion of the list of fertilisers that are eligible for subsidy.
Rs 35,000 crore investment to increase capacity by 75%.
Mohit Burman, the youngest among the newly appointed corporate heads among Dabur businesses, is known to have a penchant for acquisitions.
Interestingly, the allegations against Indian arm of the world's largest pharma maker also relates to its acquisition of the Indian subsidiary of Parke Davis by Pfizer in 2000.
Individual scientists attached to research institutions and domestic companies like Lupin, Dr Reddy's and Cadila account for the rest.
Drug banks, cancer fund now health ministry's babies.
Indian companies are unable to raise prices because 35 per cent of the drugs sold in the country come under the government's price control order.
With financial results for the quarter round the corner, small- and medium-sized, export-oriented pharmaceutical companies are expecting a 5-10 per cent decline in their bottom line for the April-June period, owing to the rupee appreciation.
Another user of the data is the clinical diabetics' consortium, which aims to identify if there are specific genetic reasons for a particular ethnic group to be predisposed to the disease.
The move is in line with the NPPA's recent policy of putting a cap on prices.
The hospital has ordered a new cath-lab and is readying its entire idle capacities to make room for Trehan's surgeons.
In April, Mumbai-based pharmaceutical company Wockhardt announced it had received five marketing approvals for its generic medicines, versions of those that have gone off patents, from the US Food and Drug Administration in five weeks.
Ranbaxy earned $114 million from its US operations in 2006. It launched 10 new products during the year. The company said that the revenues from the sale of the newly acquired brands would be reflected from the next quarter.
Shivinder's dream project, of course, is the Medicity he wants to put up at Gurgaon on the outskirts of New Delhi. That is where the problem with Trehan began, who has his own plans to come up with a similar project at Gurgaon.
Following hectic negotiations, Fortis Healthcare managing director Shivinder Singh and Naresh Trehan have finally smoked the peace pipe
After making big-ticket acquisitions abroad, leading Indian pharmaceutical companies like Dr Reddy's Laboratories, Ranbaxy Laboratories, and Aurobindo Pharma are rapidly shifting production to their Indian facilities.
With India slowly but steadily morphing into a global pharmaceutical R&D hub, scientists have run into short supply.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances